Restoring America

Conservative values, National renewal

Competition, not price controls, just slashed GLP-1 prices

Published



Novo Nordisk just announced price cuts for Ozempic and Wegovy, whose list prices as recently as last year were around $1,000 a month. Patients buying directly from the manufacturer will be able to pay as little as $349 for a monthly dose of these medicines. The company has also dropped prices for new direct-pay customers to just $199 for the first two months.

Why slash prices on blockbuster drugs? One word: competition. Its biggest rival in the GLP-1 market, Eli Lilly, has been seizing market share. Novo is looking to win customers back. Cutting prices is the most obvious way to achieve that goal.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.